Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vintafolide +/- Paclitaxel in FR+ TNBC
NCT01953536Phase 2Withdrawn
- Sponsor
- Endocyte
- Start
- Apr 2014
- Primary completion
- Nov 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules, Peptide-Drug Conjugates
01
Overview
A Phase 2 trial of vintafolide in triple-negative breast cancer (TNBC), sponsored by Endocyte. Planned start Apr 2014; status: withdrawn.
02
Drugs
vintafolide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01953536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01953536.